Search

everythinglearnresearchcommunity

for

Search:↓

Trichoscopic evaluation is important for assessing hair loss in women.

Higher GPER-1 levels are linked to more severe and shorter-duration androgenetic alopecia, suggesting GPER-1 as a potential treatment target.

More effective treatments are needed for severe alopecia areata.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

Severe COVID-19 may increase lung cancer risk and affect treatment in women due to hormonal changes.

Lower Paraoxonase 1 levels in alopecia areata patients suggest antioxidant treatment might help.

The nicotinamide supplement did not reduce symptoms in horses with insect bite hypersensitivity.

Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.

MX1 and AR genes are linked to milder COVID-19, while TMPRSS2 increases severe risk, especially in women.

Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.

Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.

The AI device accurately grades scalp exfoliation and can help diagnose scalp disorders.

Higher MPV and CRP levels may indicate more severe alopecia areata.

DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib may help treat severe hair loss, but more research is needed.

Baricitinib is effective and safe for treating severe alopecia areata.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.

Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.

Alefacept does not effectively treat severe alopecia areata.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.